PF-Atlas › Clinical Trials › NCT00131274

Gleevec Idiopathic Pulmonary Fibrosis Study

Imatinib Mesylate · Phase 2

Registry ID
NCT00131274
Phase
Phase 2
Status
Completed
Drug / intervention
Imatinib Mesylate (Gleevec)
Sponsor
Daniels, Craig E., M.D.
Start
2003-04
Enrollment
120

About this trial

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

View NCT00131274 on ClinicalTrials.gov →

Explore related

All Imatinib Mesylate trialsAll IPF trials

Related trials

Imatinib mesylate — NCT00506831Imatinib Mesylate — NCT00555581
Medical disclaimer. This page summarizes public trial data for NCT00131274 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.